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Hisashi Sakamaki,5 Masahiro Tsuchida,6 Shunichi Kato,2 Takakaza Kawase,7
Hideki Muramatsu,1 Yasuo Morishima,7 Yoshihisa Kodera8Tacrolimus (FK) and cyclosporine (CsA) have been shown to be effective in the prophylaxis of graft-versus-
host disease (GVHD). However, no comparative studies have yet been conducted to examine the efficacy of
FK/methotrexate (MTX) and CsA/MTX in patients with severe aplastic anemia (SAA) given unrelated donor
bone marrow transplantation (U-BMT).We used matched-pair analysis to compare FK/MTXwith CsA/MTX
in patients with SAA who received U-BMT through the Japan Marrow Donor Program. Forty-seven pairs
could be matched exactly for recipient age and conditioning regimens. Forty-five patients achieved engraft-
ment in the FK group and 42 patients in the CsA group. The probability of grade II-IV acute GVHD (aGVHD)
was 28.9% in the FK group and 32.6% in the CsA group (P5.558). The probability of chronic GVHD
(cGVHD) was 13.3% in the FK group and 36.0% in the CsA group (P5.104). The 5-year survival rate was
82.8% in the FK group and 49.5% in the CsA group (P5.012). The study shows the superiority of FK/
MTX over CsA/MTX in overall survival because of the lower incidence of transplantation-related deaths.
A prospective randomized study comparing FK/MTX and CsA/MTX is warranted.
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Bone marrow transplantation (BMT) from a
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However, HLA-matched related donors are available
for\30% of patients in developed countries. Immuno-
suppressive therapy (IST) has been used as an alternative
treatment for patients without a HLA-matched related
donor [3,4]. For nonresponders to IST, BMT from
an unrelated donor (U-BMT) has been indicated [5].
Acute and chronic graft-versus-host disease (aGVHD,
cGVHD) contribute to much of the morbidity and mor-
tality associated with U-BMT. Effective prevention of
these complications is therefore crucial for the success
of U-BMT.
A combination of cyclosporine (CsA) and a short
course of methotrexate (MTX) is the standard pharma-
cologic regimen for the prophylaxis of GVHD after
BMT from both HLA-matched siblings and HLA-
matched unrelated donors [6,7]. Tacrolimus (FK),
a potent macrolide lactone immunosuppressant, in-
hibits T cell activation by forming a complex with
FK binding protein-12, which blocks the serine-
threonine phosphatase activity of calcineurin [8].
Although the mechanism of action is similar to that1603
Table 1. Patient/donor Characteristics and BMT Procedure
Tacrolimus Cyclosporine P
Patient number 47 47
Age (year) .962
<10 11 11
11-29 28 27
>30 8 9
Sex .396
Male 31 27
Female 16 20
Recipient/donor sex .71
Male/male 19 19
Female/female 7 10
Male/female 12 8
Female/male 9 10
HLA matching by DNA typing .029
A, B, DRB1 match 20 34
A mismatch 4 3
B mismatch 7 0
DRB1 mismatch 7 6
2 alleles mismatch 3 2
Unknown* 6 2
Duration of disease before BMT .359
1 year or less 6 11
1-3 year 17 17
1604 Biol Blood Marrow Transplant 15:1603-1608, 2009H. Yagasaki et al.of CsA, the potency of FK in vitro is more than 100
times that of CsA [9]. This suggests that FK might
also be more effective than CsA as GVHD prophylaxis
in high-risk settings. In fact, in randomized studies of
GVHD prophylaxis after matched related and unre-
lated BMT, the incidence of aGVHD was reduced in
the treatment group receiving a combination of FK
and a short course of MTX (FK/MTX) compared to
the control group who received CsA/MTX [10-12].
However, although the number of deaths from
GVHD was lower, an increased incidence of relapse
was observed in the FK group, resulting in no differ-
ence in overall survival (OS) rate between the 2 groups.
Nevertheless, because there is no risk of relapse in pa-
tients with nonmalignant disease, the results might be
different in studies of malignant versus nonmalignant
disease. Accordingly, FK/MTX could be associated
with a lower incidence of aGVHD/cGVHD and better
survival compared to CsA/MTX in patients with ac-
quired SAA who received U-BMT.3 year or more 24 19
RBC transfusions before BMT 1
<20 7 7
20 or more 38 38
Unknown 2 2
Platelet transfusions before BMT .651
<20 9 7
20 or more 36 36
Unknown 2 4
Conditioning regimens 1
Cy + TBI + LFI + ATG 3 3
Cy + TBI + LFI 6 6
Cy + TBI + ATG 18 18
Cy + TBI 11 11
Cy + LFI + ATG 3 3
Cy + LFI 6 6
Marrow cell dose .764
<3 x 108/kg 14 13
3 x 108/kg or more 30 32
Unknown 3 2
BMT indicates bone marrow transplantation; Cy, cyclophosphamide;
TBI, total body irradiation; LFI, local field irradiation; ATG, antithymo-
cyte globulin; RBC, red blood cell.
*HLA was serologically matched or 1-antigen mismatched in these
donor-recipient pairs.METHODS
Patients and Controls
We collected U-BMT data from SAA patients
who received FK/MTX for the prophylaxis of GVHD
through the Japan Marrow Donor Program (JMDP)
database. Forty-seven patients were recruited who un-
derwent BMT between July 1997 and December
2002. For each patient receiving FK/MTX, we
selected a control patient who received CsA/MTX
for the prophylaxis of GVHD during the same period.
Because our previous study identified that recipient age
and conditioning regimens were the most important
variables associated with treatment failure, we selected
control patients matched for these 2 variables [13].
Transplantation data were collected using stan-
dardized forms provided by the JMDP. Baseline infor-
mation and follow-up reports were submitted at 100
days, 6 months, 1 year, and then annually after trans-
plantation. Analysis of patient outcome was performed
using data from the last reported follow-up or the date
of death.
Recipient-Donor HLA Matching
HLA matching between the recipient and donor
was based on HLA serotyping according to the stan-
dard technique. In 69 (73%) of the 94 recipient-donor
pairs, molecular analyses of HLA-A, -B, and -DRB1
loci were performed using DNA-based methods.
Transplantation Procedures
Various preconditioning regimens were used by
individual transplantation centers and classified into
6 categories (Table 1): (1) cyclophosphamide (Cy;120-200 mg/kg) 1 total body irradiation (TBI; 2-10
Gy)1 limited field irradiation (LFI; 5-8 Gy)1 antith-
ymocyte globulin (ATG), (2) Cy1TBI1LFI, (3)
Cy1TBI1 ATG, (4) Cy1TBI, (5) Cy1LFI -
1 ATG, and (6) Cy1LFI. For the prophylaxis of
GVHD, FK was started at a dose of 0.03 mg/kg
from day –1 and administered through continuous
24-hour i.v. infusion. Patients were converted from in-
travenous i.v. to oral intake when it could be tolerated
at a ratio of 1:3 in 2 divided doses per day based on the
last intravenous dose. Standard doses of CsA were 3
mg/kg by i.v. infusion and 6 mg/kg by oral intake.
The MTX doses were 15 mg/m2 on day 1 and 10
mg/m2 on days 3, 6, and 11 after transplantation in
both the FK and CsA groups.
Figure 1. The probability of grade II-IV aGVHD in the FK/MTX group
and the CsA/MTX group (28.9% versus 32.6%, P5.558).
Biol Blood Marrow Transplant 15:1603-1608, 2009 1605Treatment for AA Patients Who Received U-BMTDefinitions and Statistical Analysis
Engraftment was defined as achievement of a pe-
ripheral blood (PB) absolute neutrophil count (ANC)
of more than 0.5 109/L for 3 consecutive days. In
evaluation of engraftment, patients who died before
day1 22 without engraftment were not considered
evaluable. aGVHD and cGVHD were evaluated ac-
cording to the standard criteria [14,15]. Patients who
died before engraftment were excluded from the anal-
ysis of aGVHD. For analysis of cGVHD, only those
who survived 100 days after transplantation were
included. The probabilities of overall survival and
aGVHD and cGVHD were estimated from the time
of transplantation according to the Kaplan-Meier
product-limit method. The c2 test and log-rank statis-
tics were used to assess significance of differences in
variables and outcomes between the 2 groups. All
probability values were 2 sided, and P\ .05 was con-
sidered significant.Table 2. Distribution of Grade and Organ Involvement in
Acute GVHD
Tacrolimus (n5 47) Cyclosporine (n5 47)
Grade
0 22 (47%) 26 (55%)
I 7 (15%) 3 (6%)
II 8 (17%) 7 (15%)
III 4 (8%) 6 (13%)
IV 2 (5%) 1 (2%)
unevaluable 4 (8%) 4 (8%)
Organ involvement
skin 5 (38%) 3 (21%)
skin + gut 6 (46%) 7 (50%)
gut + liver 1 (8%) 0 (0%)
skin + gut + liver 1 (8%) 4 (29%)RESULTS
Patient, Donor, and Transplantation
Characteristics
Patient, donor, and transplantation characteristics
of the study population are summarized in Table 1.
There was an imbalance in HLA-A, -B, and -DRB1
allele mismatches, with 21 of the mismatch pairs ob-
served in the FK group and 11 in the CsA group
(P5 .029). Other variables were comparable between
the 2 groups.
Engraftment
Engraftment took place in 45 patients (96%) in the
FK group and 42 patients (89%) in the CsA group.
Three patients, 1 in the FK group and 2 in the CsA
group, died before day 21 and were considered not
evaluable for engraftment. One of the 46 evaluable pa-
tients in the FK group and 3 of the 45 evaluable
patients in the CsA group failed to engraft. Another
patient in the CsA group experienced late graft failure.
The median time to neutrophil recovery was 18 days in
the FK group (range: 10-28 days) and 17 days in the
CsA group (range: 12-26 days) (P5 .400).
aGVHD
The probability of grade II-IV aGVHD was
28.9% (range: 15.3%-42.5%) in the FK group and
32.6% (range: 18.4%-46.8%) in the CsA group at
100 days (Figure 1; P5 .558). aGVHD developed at
a median of 30 days (range: 7-76 days) in the FK group
and 13 days (range: 5-28 days) in the CsA group after
transplantation. The distribution of GVHD grade
and organ involvement is presented in Table 2. De-
spite the imbalance in HLA disparity, the incidenceof grade II-IV aGVHD in the FK group was equal to
that in the CsA group.
cGVHD
Thirty-eight patients in the FK group and 35 in the
CsA group were evaluable for cGVHD. Five patients
in the FK group developed cGVHD at a median pe-
riod of 4 months (range: 3-5 months) and 10 patients
in the CsA group developed cGVHD at a median pe-
riod of 4 months (range: 2-40 months). Overall, the
probability of cGVHD was 13.3% (range: 2.1%-
24.5%) in the FK group and 36.0% (range: 15.2%-
56.8%) in the CsA group (Figure 2; P5 .104). Three
patients in the FK group and 4 in the CsA group devel-
oped an extensive type of cGVHD.
Survival
Of 47 patients in each group, 39 in the FK group
survived at 4 to 61 months (median: 26 months),
whereas 25 in the CsA group survived at 3 to 61
months (median: 38 months) after transplantation.
The OS at 5 years was 82.8% (range: 71.9%-93.6%)
in the FK group and 49.5% (range: 32.5%-66.4%) in
the CsA group (Figure 3; P5 .012). Eight patients in
Figure 2. The probability of cGVHD in the FK/MTX group and the
CsA/MTX group (13.3% versus 36.0%, P5.104).
Table 3. Primary Causes of Death
Tacrolimus (n5 47) Cyclosporine (n5 47)
Bacterial/fungal infection 4 4
Graft failure 1 4
Acute GVHD 1 2
Interstitial pneumonitis 0 3
Hemorrhage 1 1
EBLPD 1 1
Heart failure 0 2
Others 0 3
Total 8 22
EBLPD indicates Epstein Barr virus associated lymphoproliferative disor-
der; GVHD, graft-versus-host disease.
1606 Biol Blood Marrow Transplant 15:1603-1608, 2009H. Yagasaki et al.the FK group and 22 in the CsA group died from trans-
plantation-related toxicities (P5 .002). Causes of
death are summarized in Table 3. Graft failure and
bacterial/fungal infection were the major causes of
death.DISCUSSION
Analyses of registration data suggest that the out-
come of U-BMT in AA patients has substantially im-
proved over the past 10 years. In analysis of 498
patients registered to the European Group for Blood
and Marrow Transplantation (EBMT), 5-year survival
increased from 32% 6 8% before to 57% 6 8% after
1998 [16]. Similarly, Maury et al. [17] analyzed the
outcome of 89 patients in the French registry and
found that 5-year survival increased from 29% 6 7%
before and 50%6 7% after 1998. An optimum condi-
tioning regimen, GVHD prophylaxis and better donor
selection may be responsible for these improvements.
In the late 1990s, HLA typing using molecular
methods was introduced into clinical use. Matching
for 10 alleles by high resolution technology replacedFigure 3. Kaplan-Meier estimates of OS in the FK/MTX group and the
CsA/MTX group (82.8% versus 49.5%, P5.012).matching for 6 antigens by low resolution technology.
A French study revealed that improved survival was as-
sociated with high-resolution HLA matching, suggest-
ing that better donor selection might be a major factor
in improving prognosis [17]. Recent attempts to im-
prove the outcome in SAA patients include the use of
low-dose TBI or a nonirradiation-fludarabine (Flu)-
based regimen. In a prospective multicenter study
sponsored by the National Marrow Donor Program
(NMDP) using low-dose TBI, a low graft rejection
rate of 5% and 5-year survival of 55% were achieved
in 87 patients [18]. Moreover, a study by the EBMT us-
ing Flu, low-dose Cy and ATG showed a lower inci-
dence of aGVHD and cGVHD and 5-year survival of
73% [19]. Although these novel pretransplant condi-
tioning regimens are promising, all analyses failed to
show the contribution of new regimens to the improved
outcomes because of the small number of patients.
Different from patients with hematologic malig-
nancies, there is no obvious benefit of GVHD for pa-
tients with AA. In fact, many studies have indicated
adverse effects of aGVHD on the outcome of AA pa-
tients, suggesting that the most effective prophylactic
regimen for GVHD should be employed for patients
with AA. However, trials involved with lessening se-
vere GVHD are limited in patients with AA. In a small
number of studies, ex vivo T cell depletion by mono-
clonal antibodies (mAbs) or in vivo use of alemtuzu-
mab instead of ATG has been attempted with
encouraging results [20,21]. Although pharmacologic
prevention with CsA/MTX is used as GVHD prophy-
laxis in the majority of AA patients, the role of alterna-
tive pharmacologic agents remains undetermined.
Although previous randomized studies comparing
CsA/MTX and FK/MTX did not show any survival
benefits of FK despite a reduction in the incidence of
aGVHD, most patients had malignant disease and
only a few with AA were included [10-12].
The aim of the present study was to compare FK
and CsA in the prophylaxis of GVHD using matched
pair analysis. One drawback was the imbalance of HLA
disparity between the 2 groups, with 21 mismatched
pairs in the FK group and 11 in the CsA group. Our
previous study showed that allelic mismatching of
Biol Blood Marrow Transplant 15:1603-1608, 2009 1607Treatment for AA Patients Who Received U-BMTHLA-A and -B antigens, but not HLA-DRB1 is the
most crucial risk factor for survival of AA patients
who received transplants from an unrelated donor
[13]. More HLA class I mismatched pairs (HLA-A;
4, HLA-B; 7) were included in the FK group than in
the CsA group (HLA-A; 3). Despite this disadvantage
in terms of HLA disparity, the probability of grade
II-IV aGVHD did not differ between the 2 groups.
The probability of cGVHD tended to be marginally
less in the FK group than in the CsA group
(P5 .104). The duration of CsA or FK after U-BMT
may affect the incidences of cGVHD. However, we
did not compare the difference of duration in this study
because the actual duration of administration of these
immunosuppressants was not available in our database.
The duration of follow-up in the FK506 group is
less than in the CSP group. Although it may introduce
a significant bias in the analysis, the current study
showed that 5-year survival was significantly higher
in the FK group than in the CsA group. Patients in
the FK group showed a significant reduction in treat-
ment-related mortality (TRM), resulting in better
OS. To date, results of 3 previous randomized studies
comparing FK and CsA have indicated a significantly
lower incidence of aGVHD among patients receiving
FK, but with no survival benefits having been demon-
strated [10-12].
Yanada et al. [22] conducted a retrospective study
comparing an FK-based regimen and CsA-based regi-
men for the prophylaxis of GVHD using registration
data of the Japan Society for Hematopoietic Cell Trans-
plantation (JSHCT). In their study, 777 patients who
underwent BMT from an unrelated donor were ana-
lyzed (FK group: n5 191, CsA group; n5 586). Al-
though the distribution of different diseases was not
specified, the majority of the patients appeared to have
hematologic malignancies. FK significantly reduced
the risk of aGVHD and TRM without any increase in
relapse, thus improving OS.
In conclusion, our matched pair analysis showed
the superiority of FK/MTX over CsA/MTX in OS.
However, our study was retrospective and a further
study comparing FK/MTX and CsA/MTX as a pro-
phylaxis of GVHD in AA patients who will receive
U-BMT may be warranted.ACKNOWLEDGMENTS
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